ozempic lawsuit Updates
Plaintiffs Seek New Jersey Multicounty Litigation for Ozempic Vision Loss Claims
In late June, 21 plaintiffs filed a request to consolidate their lawsuits in New Jersey state court through multicounty litigation (MCL), aiming to pursue joint legal action against Novo Nordisk, the maker of Ozempic and Wegovy. The plaintiffs allege they developed vision loss, specifically nonarteritic anterior ischemic optic neuropathy (NAION), after using the drugs. If approved, the MCL would allow state-level coordination of similar claims involving Ozempic-related eye damage. This move could provide a new legal pathway for affected individuals, while those experiencing other harms from Ozempic may still pursue claims through ongoing federal multidistrict litigation. A court decision is pending.
Study Links Ozempic, Wegovy to Increased Risk of Vision Loss
A new study in JAMA Ophthalmology has found that semaglutide—the active ingredient in Ozempic and Wegovy—may double the risk of developing neovascular age-related macular degeneration (nAMD), a condition that can lead to permanent central vision loss. Researchers at the University of Toronto analyzed data from nearly 140,000 type 2 diabetes patients (2020–2023), controlling for risk factors like smoking and kidney function. While the absolute risk remains low, the findings are statistically significant and biologically plausible. As concerns grow—from stomach paralysis to vision impairment—pressure is mounting on manufacturers like Novo Nordisk to address gaps in early safety research and disclosure.
New Jersey Man Alleges Wegovy Caused Permanent Vision Loss in Lawsuit Against Novo Nordisk
A Woodbridge, New Jersey, resident filed a lawsuit Thursday in New Jersey Superior Court alleging that Wegovy—a GLP-1 receptor agonist manufactured by Novo Nordisk—caused him to develop nonarteritic anterior ischemic optic neuropathy (NAION), resulting in permanent vision loss. The complaint asserts Novo Nordisk failed to warn consumers and healthcare providers of NAION risks despite knowing the drug’s potential to cause optic nerve damage. The plaintiff seeks compensatory and punitive damages for medical costs, reduced quality of life, and ongoing treatment, claiming the company prioritized marketing over safety disclosures. This case reinforces the growing legal focus on vision-loss claims linked to GLP-1 drugs, following similar petitions to consolidate NAION lawsuits in New Jersey.
New Jersey Plaintiffs Seek Multicounty Consolidation for Ozempic/Wegovy Vision Loss Lawsuits
Twenty-one New Jersey plaintiffs alleging permanent vision loss from Ozempic or Wegovy have petitioned the state’s courts to consolidate their cases into a multicounty litigation (MCL) against Novo Nordisk. The lawsuits claim the drugs caused nonarteritic anterior ischemic optic neuropathy (NAION), a rare and irreversible eye condition. Centralization aims to streamline discovery, prevent inconsistent rulings, and manage rising filings efficiently—mirroring arguments used to establish the federal gastroparesis MDL. Notably, NAION claims now eclipse earlier gastroparesis cases in legal attention due to the severity of sudden, permanent blindness. This high-stakes injury profile heightens prospects for jury trials and media scrutiny as scientific studies explore links between GLP-1 agonists and optic nerve damage.
About the Ozempic Lawsuit
The Ozempic lawsuit has recently gained significant attention as concerns have been raised about Ozempic long term side effects, including gastroparesis, thyroid C-cell tumors, and other serious illnesses.
The core issue of the Ozempic class action lawsuit is the potential serious health risks associated with the use of Ozempic, a medication commonly prescribed to manage type 2 diabetes by controlling blood sugar levels. These issues have led to numerous reports and studies focusing on the potential dangers of the active ingredient in Ozempic, semaglutide.
People afflicted with Ozempic's long-term side effects include individuals who have been prescribed the medication for diabetes management and subsequently experienced serious health issues. Individuals who used Ozempic for weight loss were unaware of the potential risks associated with the medication.
Victims who used Ozempic for weight loss are facing significant health challenges, permanent disabilities, and, in some cases, life-threatening conditions. Many people are unaware of the risks and continue using the medication, only to experience severe health issues. Legal avenues are now available for those affected, allowing them to submit an application and seek potential compensation for the harm caused by Ozempic.
If you or a loved one have suffered serious health issues after using Ozempic, it is crucial to understand your rights and the potential for participating in the Ozempic lawsuit to seek justice and compensation.
Who Qualifies for the Ozempic Lawsuit?
There are specific criteria you must meet to potentially qualify for the Ozempic lawsuit. These requirements include.
Medication Use:
You must have been prescribed and used Ozempic between 2018 and to present.
Health Conditions: You must have been diagnosed with one of the following Ozempic side effects:
- Persistent cyclical vomiting for +4 weeks (diagnosis must be while taking the product OR within 60 days of stopping and must have experienced vomiting 1 month or more)
- Gastric Injury (diagnosis must be while taking product OR within 60 days of stopping)
- A gastric injury is any injury related to the gastrointestinal tract
- Ileus
- Gastroparesis/ stomach paralysis
- Pulmonary Aspiration (associated with anesthesia/surgery)
- Deep Vein Thrombosis (DVT)
- Esophageal Injury
If you do not have a valid cancer diagnosis from your doctor but have experienced Ozempic side effects, you may still be included in the Ozempic lawsuit.
If you meet these requirements, you may be entitled to compensation and should seek legal advice to determine your eligibility.
Which Companies Are Involved in the Ozempic Lawsuit?
Several manufacturers and their respective products are commonly implicated in the Ozempic lawsuit, however, the primary company involved is Novo Nordisk. Novo Nordisk is facing numerous lawsuits alleging that the science behind Ozempic was wrong and that it has led to serious health conditions, including gastroparesis, ileus, and other significant health issues.
These Ozempic lawsuits claim that Novo Nordisk failed to adequately warn users about the potential risks associated with the drug's active ingredient, semaglutide. As more evidence emerges linking to Ozempic's long-term side effects, the number of cases against the company is expected to increase. If you or a loved one have experienced adverse health effects after using Ozempic, you may qualify to join the ongoing litigation.
How Much Compensation Should You Expect In Your Ozempic Lawsuit?
Determining a typical settlement amount in the Ozempic lawsuit is complex due to the unique nature of each case. Factors such as the severity of the illness, the strength of the evidence, jury decisions, and the skill of the lawyers involved all influence the settlement amount.
As of now, the Ozempic lawsuits are in the early stages, and no global settlements or jury trials have been reported. However, based on other pharmaceutical litigation and the current scope of the Ozempic cases, potential settlement amounts can be anticipated based on the type and extent of harm suffered by plaintiffs.
Add Comment